

**Supplementary Table 2.** Comparison of SVR rates according to clinical characteristics by genotype

Characteristic	SVR rate, % (n/total n)			
	Genotype 1b		Genotype 2	
	ITT analysis (n=667)	PP analysis (n=629)	ITT analysis (n=449)	PP analysis (n=423)
Age				
<60 years	90.7 (333/367)	97.4 (333/340)	88.9 (177/199)	96.2 (177/184)
≥60 years	92.0 (276/300)	95.9 (276/289)	92.4 (231/250)	96.7 (231/239)
Sex				
Male	91.3 (325/356)	97.9 (325/332)	87.9 (188/214)	94.5 (188/199)
Female	91.3 (284/311)	95.6 (284/297)	93.6 (220/235)	98.2 (220/224)
Liver disease status				
Chronic hepatitis	91.1 (410/450)	97.2 (410/422)	91.8 (303/330)	97.4 (303/311)
Liver cirrhosis	92.8 (154/166)	98.1 (154/157)	90.1 (73/81)	97.3 (73/75)
HCC*	88.2 (45/51)	90.0 (45/50)*	84.2 (32/38)	86.5 (32/37)*
FIB-4				
≤3.25	91.6 (362/395)	98.4 (326/268)	91.5 (270/295)	97.1 (270/278)
>3.25	90.8 (247/272)	94.6 (247/261)*	89.6 (138/154)	95.2 (138/145)
Previous IFN-based treatment				
Yes	91.3 (472/517)	97.8 (134/137)	92.9 (52/56)	98.1 (52/53)
No	91.8 (134/146)	96.7 (472/488)	90.7 (351/387)	96.4 (351/364)
Types of DAA				
DCV+ASN	89.5 (239/267)	94.1 (239/254)	100 (2/2)	100 (2/2)
SOF+RBV	100 (3/3)	100 (3/3)	91.1 (275/302)	95.5 (275/288)
LED/SOF	91.3 (115/126)	96.6 (115/119)	81.8 (9/11)	90.0 (9/10)
EBR/GRZ	91.2 (134/147)	99.3 (134/135)	100 (3/3)	100 (3/3)
GLE/PIB	98.6 (69/70)	100 (69/69)	91.2 (114/125)	99.1 (114/115)
DSV+OMV/PTV/r	92.1 (35/38)	100 (35/35)	-	-
Others	87.5 (14/16)	100 (14/14)	83.3 (5/6)	100 (5/5)

DAA, direct-acting antiviral; SVR, sustained virological response; ITT, intention-to-treat; n, number; HCC, hepatocellular carcinoma; IFN, interferon; HCV, hepatitis C virus; ALT, alanine aminotransferase; DSV+OMV/PTV/r, dasabuvir+ombitasvir/paritaprevir/ritonavir; FIB-4, fibrosis-4; DCV, daclatasvir; ASN, asunaprevir; SOF, sofosbuvir; RBV, ribavirin; LED, ledipasvir; EBR, elbasvir; GRZ, grazoprevir; GLE, glecaprevir; PIB, pibrentasvir.

\*Statistically different ( $P<0.05$ ).